S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer

Pancreatic cancer (PC) is a highly fatal and aggressive disease with its incidence and mortality quite discouraging. It is of great significance to construct an effective prognostic signature of PC and find the novel biomarker for the optimization of the clinical decision-making. Due to the crucial...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yuan Chen, Chengcheng Wang, Jianlu Song, Ruiyuan Xu, Rexiati Ruze, Yupei Zhao
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	S100A2 tumor microenvironment immune cells prognostic model immunotherapy PD-L1 Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/e60081513ee34c9ebe66633f2a913c9b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e60081513ee34c9ebe66633f2a913c9b
record_format	dspace
spelling	oai:doaj.org-article:e60081513ee34c9ebe66633f2a913c9b2021-11-30T13:06:07ZS100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer1664-322410.3389/fimmu.2021.758004https://doaj.org/article/e60081513ee34c9ebe66633f2a913c9b2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.758004/fullhttps://doaj.org/toc/1664-3224Pancreatic cancer (PC) is a highly fatal and aggressive disease with its incidence and mortality quite discouraging. It is of great significance to construct an effective prognostic signature of PC and find the novel biomarker for the optimization of the clinical decision-making. Due to the crucial role of immunity in tumor development, a prognostic model based on nine immune-related genes was constructed, which was proved to be effective in The Cancer Genome Atlas (TCGA) training set, TCGA testing set, TCGA entire set, GSE78229 set, and GSE62452 set. Furthermore, S100A2 (S100 Calcium Binding Protein A2) was identified as the gene occupying the most paramount position in risk model. Gene set enrichment analysis (GSEA), ESTIMATE and CIBERSORT algorithm revealed that S100A2 was closely associated with the immune status in PC microenvironment, mainly related to lower proportion of CD8+T cells and activated NK cells and higher proportion of M0 macrophages. Meanwhile, patients with high S100A2 expression might get more benefit from immunotherapy according to immunophenoscore algorithm. Afterwards, our independent cohort was also used to demonstrate S100A2 was an unfavorable marker of PC, as well as its remarkably positive correlation with the expression of PD-L1. In conclusion, our results demonstrate S100A2 might be responsible for the preservation of immune-suppressive status in PC microenvironment, which was identified with significant potentiality in predicting prognosis and immunotherapy response in PC patients.Yuan ChenChengcheng WangJianlu SongRuiyuan XuRexiati RuzeYupei ZhaoFrontiers Media S.A.articleS100A2tumor microenvironmentimmune cellsprognostic modelimmunotherapyPD-L1Immunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	S100A2 tumor microenvironment immune cells prognostic model immunotherapy PD-L1 Immunologic diseases. Allergy RC581-607
spellingShingle	S100A2 tumor microenvironment immune cells prognostic model immunotherapy PD-L1 Immunologic diseases. Allergy RC581-607 Yuan Chen Chengcheng Wang Jianlu Song Ruiyuan Xu Rexiati Ruze Yupei Zhao S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer
description	Pancreatic cancer (PC) is a highly fatal and aggressive disease with its incidence and mortality quite discouraging. It is of great significance to construct an effective prognostic signature of PC and find the novel biomarker for the optimization of the clinical decision-making. Due to the crucial role of immunity in tumor development, a prognostic model based on nine immune-related genes was constructed, which was proved to be effective in The Cancer Genome Atlas (TCGA) training set, TCGA testing set, TCGA entire set, GSE78229 set, and GSE62452 set. Furthermore, S100A2 (S100 Calcium Binding Protein A2) was identified as the gene occupying the most paramount position in risk model. Gene set enrichment analysis (GSEA), ESTIMATE and CIBERSORT algorithm revealed that S100A2 was closely associated with the immune status in PC microenvironment, mainly related to lower proportion of CD8+T cells and activated NK cells and higher proportion of M0 macrophages. Meanwhile, patients with high S100A2 expression might get more benefit from immunotherapy according to immunophenoscore algorithm. Afterwards, our independent cohort was also used to demonstrate S100A2 was an unfavorable marker of PC, as well as its remarkably positive correlation with the expression of PD-L1. In conclusion, our results demonstrate S100A2 might be responsible for the preservation of immune-suppressive status in PC microenvironment, which was identified with significant potentiality in predicting prognosis and immunotherapy response in PC patients.
format	article
author	Yuan Chen Chengcheng Wang Jianlu Song Ruiyuan Xu Rexiati Ruze Yupei Zhao
author_facet	Yuan Chen Chengcheng Wang Jianlu Song Ruiyuan Xu Rexiati Ruze Yupei Zhao
author_sort	Yuan Chen
title	S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer
title_short	S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer
title_full	S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer
title_fullStr	S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer
title_full_unstemmed	S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer
title_sort	s100a2 is a prognostic biomarker involved in immune infiltration and predict immunotherapy response in pancreatic cancer
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/e60081513ee34c9ebe66633f2a913c9b
work_keys_str_mv	AT yuanchen s100a2isaprognosticbiomarkerinvolvedinimmuneinfiltrationandpredictimmunotherapyresponseinpancreaticcancer AT chengchengwang s100a2isaprognosticbiomarkerinvolvedinimmuneinfiltrationandpredictimmunotherapyresponseinpancreaticcancer AT jianlusong s100a2isaprognosticbiomarkerinvolvedinimmuneinfiltrationandpredictimmunotherapyresponseinpancreaticcancer AT ruiyuanxu s100a2isaprognosticbiomarkerinvolvedinimmuneinfiltrationandpredictimmunotherapyresponseinpancreaticcancer AT rexiatiruze s100a2isaprognosticbiomarkerinvolvedinimmuneinfiltrationandpredictimmunotherapyresponseinpancreaticcancer AT yupeizhao s100a2isaprognosticbiomarkerinvolvedinimmuneinfiltrationandpredictimmunotherapyresponseinpancreaticcancer
_version_	1718406596533420032

S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer

Ejemplares similares